E7777
Phase 3Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral T-Cell Lymphoma
Conditions
Peripheral T-Cell Lymphoma
Trial Timeline
Mar 1, 2011 → Nov 1, 2014
NCT ID
NCT01355783About E7777
E7777 is a phase 3 stage product being developed by Eisai for Peripheral T-Cell Lymphoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01355783. Target conditions include Peripheral T-Cell Lymphoma.
What happened to similar drugs?
9 of 20 similar drugs in Peripheral T-Cell Lymphoma were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02676778 | Phase 2 | Completed |
| NCT01355783 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Peripheral T-Cell Lymphoma